What was the market valuation of the UK vaccine technologies market in 2024?

The market valuation was $1882.24 Million in 2024. Read More

What is the projected market valuation for the UK vaccine technologies market by 2035?

The projected valuation for 2035 is $5809.21 Million. Read More

What is the expected CAGR for the UK vaccine technologies market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period is 10.79%. Read More

Which companies are considered key players in the UK vaccine technologies market?

Key players include Pfizer, Moderna, AstraZeneca, Johnson & Johnson, Sanofi, GSK, Novavax, Merck, and Bharat Biotech. Read More

What was the market size for the Recombinant/Conjugate/Subunit segment in 2024?

The market size for the Recombinant/Conjugate/Subunit segment was $600.0 Million in 2024. Read More

How does the market size for Pediatric vaccines compare to Adult vaccines in 2024?

In 2024, the market size for Pediatric vaccines was $376.45 Million, whereas Adult vaccines reached $1505.79 Million. Read More

What distribution channels are utilized in the UK vaccine technologies market?

Distribution channels include Hospital & Retail Pharmacies, Government Suppliers, and Others. Read More

What was the market size for Government Suppliers in 2024?

The market size for Government Suppliers was $944.0 Million in 2024. Read More

What is the projected market size for Viral Diseases by 2035?

The projected market size for Viral Diseases by 2035 is $3485.25 Million. Read More

UK Vaccine Technologies Market

Q: What are the main segments of the UK vaccine technologies market by type?

The main segments by type include Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated, and Toxoid. Read More

ID: MRFR/Pharma/50282-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

UK Vaccine Technologies Market Research Report By Type (Recombinant, Conjugate, Subunit, Inactivated, Live Attenuated, Toxoid), By Route of Administration (Parenteral, Oral), By Disease Indication (Viral Diseases, Bacterial Diseases), By Age Group (Pediatric, Adults) andBy Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others) - Growth & Industry Forecast 2025 To 2035

UK Vaccine Technologies Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)10.79%

2024 Market Size$ 1,882.24 Million

2025 Market Size$ 2,085.33 Million

2035 Market Size$ 5,809.21 Million

Key Players

Pfizer

Moderna

AstraZeneca

Johnson & Johnson

Sanofi

GSK

Trends

Emergence of Novel Vaccine Platforms
Increased Public-Private Partnerships
Focus on Personalized Vaccination Strategies

Opportunities

Growing Demand for Vaccination Programs
Integration of Digital Health Technologies
Advancements in Biomanufacturing Techniques

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Type (USD Million)
  1. 4.1.1 Recombinant/Conjugate/Subunit
  2. 4.1.2 Inactivated
  3. 4.1.3 Live Attenuated
  4. 4.1.4 Toxoid
2. 4.2 Pharmaceutical, BY Route of Administration (USD Million)
  1. 4.2.1 Parenteral
  2. 4.2.2 Oral
3. 4.3 Pharmaceutical, BY Disease Indication (USD Million)
  1. 4.3.1 Viral Diseases
  2. 4.3.2 Bacterial Diseases
4. 4.4 Pharmaceutical, BY Age Group (USD Million)
  1. 4.4.1 Pediatric
  2. 4.4.2 Adults
5. 4.5 Pharmaceutical, BY Distribution Channel (USD Million)
  1. 4.5.1 Hospital & Retail Pharmacies
  2. 4.5.2 Government Suppliers
  3. 4.5.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Moderna (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 GSK (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novavax (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bharat Biotech (IN)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY TYPE
3. 6.3 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 UK MARKET ANALYSIS BY DISEASE INDICATION
5. 6.5 UK MARKET ANALYSIS BY AGE GROUP
6. 6.6 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
7. 6.7 KEY BUYING CRITERIA OF PHARMACEUTICAL
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF PHARMACEUTICAL
10. 6.10 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
12. 6.12 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
14. 6.14 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
15. 6.15 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
16. 6.16 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
17. 6.17 PHARMACEUTICAL, BY DISEASE INDICATION, 2024 (% SHARE)
18. 6.18 PHARMACEUTICAL, BY DISEASE INDICATION, 2024 TO 2035 (USD Million)
19. 6.19 PHARMACEUTICAL, BY AGE GROUP, 2024 (% SHARE)
20. 6.20 PHARMACEUTICAL, BY AGE GROUP, 2024 TO 2035 (USD Million)
21. 6.21 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
22. 6.22 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY DISEASE INDICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY AGE GROUP, 2025-2035 (USD Million)
  5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK UK Vaccine Technologies Market Segmentation

UK Vaccine Technologies Market By Type (USD Million, 2025-2035)

Recombinant/Conjugate/Subunit
Inactivated
Live Attenuated
Toxoid

UK Vaccine Technologies Market By Route of Administration (USD Million, 2025-2035)

Parenteral
Oral

UK Vaccine Technologies Market By Disease Indication (USD Million, 2025-2035)

Viral Diseases
Bacterial Diseases

UK Vaccine Technologies Market By Age Group (USD Million, 2025-2035)

Pediatric
Adults

UK Vaccine Technologies Market By Distribution Channel (USD Million, 2025-2035)

Hospital & Retail Pharmacies
Government Suppliers
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”